Suven Pharmaceuticals Limited (NSE:SUVENPHAR)
India
· Delayed Price · Currency is INR | Market Cap | 297.36B |
| Revenue (ttm) | 10.48B |
| Net Income (ttm) | 2.79B |
| Shares Out | 254.56M |
| EPS (ttm) | 10.93 |
| PE Ratio | 106.84 |
| Forward PE | 64.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,155 |
| Average Volume | 412,720 |
| Open | 1,195.70 |
| Previous Close | 1,195.70 |
| Day's Range | 1,165.00 - 1,205.50 |
| 52-Week Range | 598.00 - 1,360.00 |
| Beta | 1.34 |
| RSI | 54.06 |
| Earnings Date | May 28, 2025 |
About Suven Pharmaceuticals
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited. [Read more]
Financial Performance
In 2023, Suven Pharmaceuticals's revenue was 10.51 billion, a decrease of -21.56% compared to the previous year's 13.40 billion. Earnings were 3.00 billion, a decrease of -26.99%.
Financial StatementsNews
Suven Pharma shares surge 3% as Goldman Sachs initiates ‘Buy’ rating with Rs 1,350 target
Suven Pharmaceuticals saw its shares rise by 3% following Goldman Sachs’ bullish outlook, as the global brokerage initiated coverage with a ‘Buy’ rating and a target price of ₹1,350. The firm expects ...
Goldman Sachs initiates ‘Buy’ call on Suven Pharma shares, expects 28% upside in stock price
Goldman Sachs has initiated coverage on Suven Pharmaceuticals with a ‘Buy’ rating and a target price of ₹1,350, expecting a sharp recovery and structural growth beginning FY26. The brokerage expects g...
NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals
Hyderabad: The National Company Law Tribunal has sanctioned the scheme of amalgamation between contract development and manufacturing organisation (CD.
Stock recommendations by brokers for March 26
CLSA maintains high conviction on Bandhan Bank with enhancements in secured assets and technology as key priorities. Jefferies retains 'buy' on Infosys but reduces target price due to slower growth. H...
Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential
Shares of Suven Pharmaceuticals Ltd soared 12% today after Macquarie Equity Research initiated an ‘Outperform’ rating on multiple contract research, development, and manufacturing (CRDMO) companies, i...
Suven Pharma shares surge over 3% as Macquarie initiates ‘Outperform’ call with target price of Rs 1,500
Suven Pharmaceuticals saw a strong rally in its stock price, jumping over 3% after global brokerage Macquarie initiated an Outperform rating. The firm has set a target price of ₹1,500, citing Suven’s ...
Top market gainers: Suven Pharma jumps 9.41%, Godrej Industries up 9.15%, Muthoot Finance gains 5.91%
The Indian stock market witnessed strong buying interest in early trade, with several stocks emerging as top gainers. Leading the rally was Suven Pharmaceuticals, which surged 9.41% to ₹1,146.80, refl...
Suven Pharma shares jump 7% as Q3 net profit rises 77% YoY
Suven Pharmaceuticals Ltd saw its shares jump over 7% in morning trade after posting impressive Q3 FY25 results. As of 9:32 AM, the shares were trading 7.62% higher at Rs 1,128.05. The company reporte...
Suven Pharmaceuticals acquires 56% stake in NJ Bio for Rs 533 crore
This development aligns with Suven’s vision to broaden its footprint in high-growth areas of the healthcare industry while delivering enhanced value to its shareholders.
Suven Pharma acquires 56% stake in US-based NJ Bio
Suven Pharmaceuticals Limited has announced the acquisition of a 56% stake in NJ Bio Inc for $64.4 million, enhancing its R&D and manufacturing footprint in the antibody drug conjugate market, project...
Suven Pharmaceuticals acquires 56% stake in NJ Bio for Rs 534.52 crore
Suven Pharmaceuticals Limited, a leading Contract Development and Manufacturing Organization (CDMO) has announced its acquisition of a 56% stake in NJ Bio Inc., an advanced ADC (Antibody-Drug Conjugat...
Suven Pharma shares surge 3% after appointment of Vivek Sharma as Executive Chairman
Suven Pharmaceuticals announced the appointment of Vivek Sharma as its new Executive Chairman, effective September 20, 2024. This move follows the transition of Vaidheesh Annaswamy, who will now serve...